August 31, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2606997

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI

Listen to this summary

The study aimed to evaluate the safety and efficacy of omitting aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) by comparing low-dose prasugrel monotherapy to dual antiplatelet therapy (DAPT) with aspirin. The results indicated that prasugrel monotherapy was not noninferior to DAPT regarding the composite outcome of death, stroke, or myocardial infarction at 12 months, although it was associated with a lower rate of major bleeding.

Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino, Kosuke Kashiwabara, Hiromasa Otake, Satoru Suwa, Mamoru Nanasato, Takashi Muramatsu, Hitoshi Anzai, Akihiro Shirakabe, Masashi Yamamoto, Yasuhide Asaumi, Masashi Sakuma, Hideki Okayama, Keisuke Nakabayashi, Nobuhiko Ogata, Kentaro Jujo, Kohei Wakabayashi, Takanori Kusuyama, Yuko Onishi, Kazuhiro Ashida, Yuya Mitsuhashi, Yuji Nishimoto, Seiji Yamazaki, Nehiro Kuriyama, Yuji Ikari, Gaku Nakazawa, PREMIUM Trial Investigators

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play